News

Edluar, which was developed by Orexo using its proprietary sublingual formulation technologies, is indicated for treatment of insomnia characterized by difficulties with sleep initiation. Orexo chief executive officer

The collaboration will apply KineMed’s biomarker discovery platform in therapeutic areas of interest to GSK. KineMed president and CEO David Fineman said, "The marriage of KineMed’s insights into

EIA is used for Quantitative Determination of anti-Angiotensin II Receptor 1 (AT1) Antibodies. The application screens antibodies that form against Angiotensin II Type I Receptors (AT1R). AT1R involves

Perceptive Informatics, PAREXEL’s technology subsidiary, developed the fully-integrated eClinical platform. PAREXEL chief operating officer Mark Goldberg said with the availability of PAREXEL MyTrials, users will have a single

As part of the collaboration Protagonist will provide a valid and proprietary technology platform for the discovery and optimisation of novel DRPs (disulfide rich peptides). Zealand Pharma will

The proposed filling line is expected produce up to 1 million units per day and is well suited for the aseptic filling of high-volume products, like vaccines. The

The study’s independent Data Monitoring Committee concluded that the treatment with saridegib was similar to placebo and, hence, the trial would not meet its primary endpoint, the progression-free

The collaboration will focus on improving patient health outcomes through new solutions that aid shared decision making between patients and physicians. Geisinger Health System president and chief executive

Duexis is used for the relief of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper gastrointestinal ulcers. Mallinckrodt,will promote Duexis to targeted physicians and